NGENLA Drug Profile

Summary for Tradename: NGENLA

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Pharmacology for NGENLA

Mechanism of Action	11-beta Hydroxysteroid Dehydrogenase Type 1 Inhibitors
Established Pharmacologic Class	Recombinant Human Growth Hormone
Chemical Structure	Human Growth Hormone

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for NGENLA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for NGENLA Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for NGENLA Derived from Patent Text Search

No patents found based on company disclosures

NGENLA Market Dynamics, Patent Position, Competition, and Financial Trajectory

Last updated: September 9, 2026

NGENLA, Pfizer’s once-weekly growth hormone based on somatrogon-ghla, is competing in a mature but reformulating pediatric growth-hormone market. Its commercial proposition is reduced injection frequency versus daily recombinant human growth hormone. The principal risks are payer restrictions, physician and patient switching costs, entrenched daily products, and competition from other long-acting growth-hormone therapies.

Pfizer has not publicly disclosed a standalone NGENLA revenue line in its principal financial reporting. Financial performance therefore must be assessed through launch geography, market access, prescription adoption, the long-acting growth-hormone segment, and Pfizer’s broader product disclosures rather than a verified product-level revenue series.

What is NGENLA and how does it work?

NGENLA is the U.S. brand for somatrogon-ghla, a long-acting recombinant human growth-hormone analog. It is administered once weekly for pediatric patients at least 3 years old who have growth failure caused by inadequate secretion of endogenous growth hormone.[1]

Somatrogon combines the amino-acid sequence of human growth hormone with three copies of the C-terminal peptide of the beta subunit of human chorionic gonadotropin. The modification extends systemic exposure and supports weekly administration.[1]

Attribute	NGENLA
Active ingredient	Somatrogon-ghla
Drug class	Long-acting recombinant growth hormone
U.S. sponsor	Pfizer
Original development partner	OPKO Health
U.S. approval	June 28, 2023
U.S. indication	Pediatric growth hormone deficiency in patients aged 3 years and older
Administration	Once weekly, subcutaneous injection
Regulatory pathway	Biologics license application
Primary commercial advantage	Weekly rather than daily dosing

The FDA approval was supported by a randomized Phase 3 study comparing once-weekly somatrogon with once-daily Genotropin in prepubertal children with growth hormone deficiency. The study met its primary growth-velocity endpoint, although the products were not clinically interchangeable in a simple therapeutic or regulatory sense.[2]

When did NGENLA launch in major markets?

NGENLA has a staggered international launch profile. The product obtained approvals in Japan, the European Union, Canada, and the United States across 2021 to 2023.

Market	Regulatory milestone	Commercial significance
Canada	Approved in 2021	Early commercial validation for pediatric weekly dosing
Japan	Approved in 2022	Access to a significant growth-hormone market
European Union	Approved in 2022	Entry into multiple national reimbursement systems
United States	FDA approval on June 28, 2023	Largest single commercial opportunity and strongest pricing market

In the United States, Pfizer markets NGENLA through a specialty-product model involving endocrinology practices, specialty pharmacies, patient-support services, and payer authorization processes. The product is not an over-the-counter or conventional retail prescription medicine. Treatment typically requires diagnosis confirmation, specialist prescribing, and continuing insurance review.

How large is the long-acting growth-hormone market?

The addressable market is the global pediatric growth-hormone market, with the most attractive segment consisting of patients and caregivers who place a high value on reducing injection frequency.

Daily growth-hormone products remain entrenched. Major brands include:

• Genotropin, marketed by Pfizer
• Norditropin, marketed by Novo Nordisk
• Humatrope, marketed by Eli Lilly
• Omnitrope, marketed by Sandoz
• Saizen, marketed by Merck in selected markets
• Valtropin and other regional products

Long-acting competitors include:

• Skytrofa, or lonapegsomatropin-tcgd, marketed by Ascendis Pharma
• Sogroya, or somapacitan-beco, marketed by Novo Nordisk
• NGENLA, or somatrogon-ghla, marketed by Pfizer

The relevant market is not defined only by diagnosed growth hormone deficiency. It is also shaped by:

1. Diagnosis rates and pediatric endocrinology capacity.
2. Insurance coverage and prior authorization.
3. Family acceptance of injections.
4. Device usability and storage requirements.
5. Reimbursement relative to daily products.
6. Physician confidence in switching stable patients.
7. Long-term adherence and persistence.

The weekly category can expand the value of the market by improving adherence, but weekly dosing does not automatically create new diagnoses. Commercial growth will depend primarily on switching from daily products and increasing treatment persistence.

How does NGENLA compare with Skytrofa and Sogroya?

NGENLA competes on the same central attribute as Skytrofa and Sogroya: fewer injections. Product differentiation is based on clinical evidence, device design, dosing flexibility, supply reliability, payer contracts, and physician relationships.

Product	Company	Molecule	Dosing frequency	Key competitive issue
NGENLA	Pfizer	Somatrogon-ghla	Weekly	Pfizer’s global infrastructure and established growth-hormone presence
Skytrofa	Ascendis Pharma	Lonapegsomatropin-tcgd	Weekly	Early long-acting entrant and proprietary TransCon technology
Sogroya	Novo Nordisk	Somapacitan-beco	Weekly	Novo Nordisk’s endocrine commercial platform and broader metabolic presence
Genotropin	Pfizer	Somatropin	Daily	Existing physician familiarity and Pfizer’s incumbent franchise
Norditropin	Novo Nordisk	Somatropin	Daily	Scale, established reimbursement, and endocrinology relationships
Humatrope	Eli Lilly	Somatropin	Daily	Long market history and installed prescriber base

NGENLA’s strongest strategic advantage is Pfizer’s existing relationships in growth hormone. Its main internal risk is cannibalization of Genotropin. A successful NGENLA launch can increase Pfizer’s share of long-acting treatment while reducing sales of its daily product.

Skytrofa benefits from an earlier U.S. launch and a technology platform designed around extended-release biologics. Sogroya benefits from Novo Nordisk’s substantial endocrinology and specialty-care infrastructure. NGENLA must therefore compete against both established daily brands and specialist long-acting entrants.

What is NGENLA’s FDA regulatory and exclusivity status?

NGENLA is regulated as a biologic under a biologics license application. It is not listed in the FDA Orange Book because the Orange Book primarily covers approved drug products submitted through new drug applications.

The relevant U.S. reference-product exclusivity period is the 12-year biologic exclusivity period established under the Biologics Price Competition and Innovation Act. Based on the June 28, 2023 approval date, the statutory reference-product exclusivity period runs to June 28, 2035, subject to the operation of pediatric exclusivity or other applicable legal provisions.[3]

U.S. exclusivity issue	NGENLA position
BLA approval	June 28, 2023
Reference-product exclusivity	Generally 12 years from first licensure
Expected base date	June 28, 2035
Orange Book listing	No
Biosimilar pathway	Available after applicable statutory timing
Pediatric exclusivity	Must be assessed from FDA-recognized pediatric studies and the applicable exclusivity record

Biologic exclusivity does not mean the product is protected only by one date. Patent terms, regulatory exclusivity, pediatric exclusivity, patent-term adjustment, patent-term extension, and litigation timing can produce different market-entry outcomes.

What patents protect NGENLA?

NGENLA is protected by a combination of composition, fusion-protein, formulation, manufacturing, dosing, and device-related intellectual property. The commercial product originated from technology developed by OPKO and licensed to Pfizer.[4]

The most important patent categories are:

Somatrogon composition patents

These patents cover long-acting growth-hormone fusion proteins incorporating the C-terminal peptide of human chorionic gonadotropin. Composition claims are generally the strongest form of protection because they can cover the active molecule across multiple formulations and uses.

Formulation patents

Formulation claims may cover the concentration, excipients, stability profile, pH, or storage conditions needed to commercialize somatrogon. Their value depends on whether a competing biosimilar can use a non-infringing formulation while maintaining comparable product performance.

Method-of-use patents

Potential method claims may address treatment of pediatric growth hormone deficiency, dosing schedules, patient populations, or weekly administration. Method-of-use patents can support litigation but are more vulnerable to label carve-outs and prescribing-practice arguments than composition claims.

Manufacturing patents

Manufacturing protection may cover recombinant production, purification, conjugation or fusion-protein processing, and formulation or filling steps. Manufacturing patents can delay biosimilar commercialization even where the biosimilar uses the same active molecule.

Device and delivery patents

The commercial product depends on a prefilled or pen-based injection system and associated administration components. Device claims can create incremental barriers but usually do not provide the same protection as active-molecule claims.

NGENLA does not have the same Orange Book patent-listing framework as a small-molecule drug. Patent disputes involving a biosimilar would generally proceed through the BPCIA patent-exchange process rather than a conventional Hatch-Waxman Paragraph IV certification.

Are there Paragraph IV challenges to NGENLA?

No conventional Paragraph IV challenge is expected because NGENLA is licensed under a BLA rather than approved under an NDA. A future biosimilar applicant would generally rely on the BPCIA framework, including the statutory patent-information exchange often called the “patent dance,” rather than an Orange Book Paragraph IV certification.

As of the publicly reported regulatory record through mid-2024, there was no widely reported U.S. biosimilar litigation involving NGENLA. The absence of litigation at that stage is consistent with the product’s recent approval and the long period before statutory reference-product exclusivity expires.

The earliest credible U.S. biosimilar competition is more likely to be determined by:

• The scope and expiry of composition patents.
• Whether a biosimilar applicant accepts or contests listed patent claims.
• Patent-term adjustment or extension.
• The timing of FDA biosimilar approval.
• Settlement terms.
• Whether the biosimilar launches with a carved-out label.
• Manufacturing and interchangeability strategy.

What is the commercial impact of NGENLA on Pfizer?

NGENLA has strategic value beyond its direct sales. It gives Pfizer a weekly product that can defend the company’s position as daily growth-hormone products lose differentiation and long-acting competitors gain share.

The financial trajectory has four stages:

Launch phase

The 2023 U.S. approval established the product in Pfizer’s largest commercial market. Initial sales were likely constrained by payer placement, specialty-pharmacy onboarding, physician education, and patient-support enrollment.

Access expansion

The next phase depends on formulary inclusion and conversion of existing daily growth-hormone patients. Reimbursement negotiations are likely to determine whether NGENLA is preferred, non-preferred, or subject to step therapy.

Portfolio migration

Pfizer can shift selected Genotropin patients to NGENLA. This can protect Pfizer’s growth-hormone franchise while limiting net portfolio growth if NGENLA largely replaces Genotropin revenue.

Mature competition

As Skytrofa and Sogroya expand, the long-acting market may become more price competitive. NGENLA’s growth rate will then depend on persistence, contracting, supply, clinical differentiation, and international reimbursement.

Pfizer’s public filings do not provide a consistently reported standalone NGENLA sales series. The product’s revenue is therefore not independently verifiable from Pfizer’s consolidated disclosures. That limits precise calculation of product-level growth, peak sales, margin, and return on investment.

What licensing deal supports NGENLA?

Pfizer licensed rights to somatrogon from OPKO Health. Under the agreement, Pfizer assumed global development and commercialization responsibilities, while OPKO retained economic participation through milestone payments and royalties.[4]

The transaction gave Pfizer access to a long-acting growth-hormone asset without having to develop the underlying platform internally. OPKO received the benefit of Pfizer’s regulatory, manufacturing, and commercial infrastructure.

The deal’s economics create a shared-value structure:

• Pfizer carries commercialization and market-access costs.
• OPKO receives milestones and royalties.
• Pfizer gains a potential successor to or complement for Genotropin.
• The commercial outcome depends on the conversion rate from daily to weekly treatment.

What generic or biosimilar launch risks exist for NGENLA?

Near-term biosimilar risk is limited by the product’s recent approval and statutory biologic exclusivity. Longer-term risk remains material because growth hormone is a biologic category with established manufacturing expertise and multiple commercial competitors.

The likely launch scenarios are:

Scenario	Timing logic	Commercial effect
No early biosimilar challenge	Patent and exclusivity barriers remain effective	Pfizer retains pricing and share
Patent settlement	Entry occurs before full patent expiry under negotiated terms	Gradual erosion, often with limited initial competition
First biosimilar launch	One approved competitor enters	Payers gain leverage and switching accelerates
Multiple biosimilars	Several suppliers compete	Greater price pressure and formulary displacement
Long-acting substitute competition	Weekly alternatives gain preference	NGENLA loses share without a biosimilar entering

Biosimilar substitution may also be slower than in small-molecule markets because pediatric endocrinologists and caregivers may be reluctant to change a stable patient’s product. Interchangeability designation, device familiarity, and payer policy will influence switching.

How strong is the NGENLA patent estate?

The estate is commercially meaningful because it is supported by biologic exclusivity, active-molecule technology, formulation know-how, manufacturing expertise, and Pfizer’s global commercial position. Its strength cannot be reduced to one patent expiration date.

The strongest barriers are likely the core somatrogon composition and fusion-protein claims. Formulation, dosing, and manufacturing patents provide additional layers but may be easier for biosimilar developers to design around or challenge.

The estate’s practical strength is also affected by:

• Claim breadth.
• Patent prosecution history.
• Validity under obviousness and written-description standards.
• Enablement of the full claimed genus.
• Freedom-to-operate around the delivery device.
• Patent-term adjustment.
• International claim scope.
• Manufacturing location and supply-chain control.

NGENLA has no known major publicly reported U.S. patent judgment or settlement that would establish an earlier biosimilar entry date.

What is the geographic opportunity for NGENLA?

The United States is the most important single market because of product pricing and the size of specialty pharmaceutical spending. Europe offers broad geographic reach but fragmented national reimbursement. Japan and Canada provide established growth-hormone markets with different payer and prescribing dynamics.

Pfizer’s global footprint is an advantage in markets where regulatory approval, supply reliability, and local reimbursement execution matter. It is less decisive where national health systems impose reference pricing or require substantial price concessions.

International growth will therefore be uneven. A product may achieve strong clinical uptake in one country while remaining restricted in another because of health technology assessment outcomes or tender-based purchasing.

Key takeaways

• NGENLA is Pfizer’s once-weekly somatrogon growth-hormone product for pediatric growth hormone deficiency.
• Its commercial value depends on switching from daily growth hormone and improving treatment persistence.
• The main competitors are Ascendis Pharma’s Skytrofa and Novo Nordisk’s Sogroya.
• Pfizer has not disclosed a reliable standalone NGENLA revenue series in its principal public financial reporting.
• The product received FDA approval on June 28, 2023, creating a base 12-year biologic exclusivity period to June 28, 2035.
• NGENLA is not an Orange Book product and is not expected to face a conventional Paragraph IV challenge.
• Future biosimilar disputes would generally proceed under the BPCIA framework.
• Pfizer’s ownership of Genotropin creates both a distribution advantage and a cannibalization risk.
• Core somatrogon composition protection is likely more important than formulation, method-of-use, or device patents.
• Long-term pricing pressure will depend on biosimilar entry, payer contracting, and competition from other weekly growth-hormone products.

FAQs about NGENLA

Is NGENLA a biosimilar to Genotropin?

No. NGENLA is a distinct long-acting growth-hormone analog. It is not a biosimilar to Genotropin, which contains somatropin.

Can NGENLA be substituted automatically for daily growth hormone?

Automatic substitution depends on jurisdiction, product labeling, payer policy, and whether a product has the relevant interchangeability designation. Clinical switching is generally managed by the prescribing specialist.

Who developed the active ingredient in NGENLA?

OPKO Health developed the underlying somatrogon technology and licensed it to Pfizer for development and commercialization.

Does NGENLA compete with obesity drugs?

No. NGENLA is a pediatric endocrine treatment for growth hormone deficiency. Its commercial market is distinct from GLP-1 medicines and other obesity therapies.

What will determine NGENLA peak sales?

Peak sales will depend on weekly growth-hormone adoption, U.S. payer access, international reimbursement, conversion from Genotropin and other daily products, pricing relative to Skytrofa and Sogroya, and the timing of biosimilar or substitute-product entry.

References

1. U.S. Food and Drug Administration. (2023). NGENLA (somatrogon-ghla) prescribing information.
2. Pfizer Inc. (2023). FDA approves NGENLA, a once-weekly treatment for pediatric growth hormone deficiency.
3. Biologics Price Competition and Innovation Act, 42 U.S.C. § 262.
4. OPKO Health, Inc. (2023). Annual report on Form 10-K for fiscal year 2023.
5. Pfizer Inc. (2023). Annual report on Form 10-K for fiscal year 2023.
6. European Medicines Agency. (2022). Ngenla: EPAR product information.